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812-1 Fenofibrate Induces Plaque Regression in 
Hypercholesterolemic Atherosclerotic Rabbits: In Vivo 
Demonstration by High-Resolution Magnetic Resource 
Imaging 
Roberto Cortl, Julio I. Osende, John T. Fallon, Urooj Zafar, Valentin Fuster. Gabor 
Mizsei. Ham Jneid, Juan J. Badimon, Mount Sinai School of Medicine, New York, NY 
Introduction: Fenofibrate has shown to reduce major cardiovascular events and slow 
angiographic progression of coronary atherosclerosis. Its postulate mechanism of action 
is through adwation of peroxlsomal proliferator-activated receptor-alpha, a nuclear tran- 
scription factor that controls a van&y of cellular functions. We investigated the anti- 
atherogenic effects of fenofibrate on previously established experimental atherosclerotic 
(AT) lesions. 
Method AT-lesions were induced in NZW rabbits (n=24) by a combination of double bal- 
loon-mjury and g-month hypercholesterolemlc (HC) diet. At the end of the AT-inductton 
period all rabbits underwent MRI and 7 of them were sacrificed, processed for histology, 
and served as AT-control. The remaining animals were randomized into 3 groups: [l] 
resuming standard chow (n=5), [2] HC-diet+placebo (n=6) and [3] HC-diet+fenofibrate 
(n=6). Rabbits underwent an additional MRI after 6 months of treatment, and were then 
sacrificed for histopathology. 
Results MRI showed that all groups had similar vessel wall area (VWA) at randomization. 
Significant increase in VWA was seen in the HC-diet+placebo group (15%*4%. p=O.O07 
vs. baseline). In the group resuming standard chow, progression was abolished (- 
2.5+3%, ~~0.37 vs. baseline). The fenofibrate group had significant plaque regression (- 
11+4%, p=O.O41) despite maintalned HC-diet. Plasma lipid levels were normalized in 
standard chow group, whereas they remamed elevated m both, the HC-diet+placebo and 
HC-diet+fenofibrate groups. Hlstopathological analysis, to define vascular biology of the 
different treatment groups, IS under investigation. 
Conclusion Our data indicate that normalization of plasma lipid levels abolishes athero- 
sclerosis progression. Fenofibrate elicits regression of atherosclerotic lesions indepen- 
dently of the plasma lipid levels. These observations support the lipid-Independent 
mechanism of action and the anti-atherogenic benefits of fenofibrate, supporting the 
potential antiatherogenic effect of PPAR-alpha agonists. 
11:15 a.m. 
812-2 E-Selectin and P-Selectin Are Markers of Aortic Plaque 
Burden as Measured by Transesophageal Magnetic 
Resource Imaging 
William P. Warren, Sandeeo Gautam Henning Steen, Shenghan Lai, Subroto 
Chatterfee. Joao Lima, Johns Hopkins University School of Medicine, Baltimore, MD 
Background: Cellular adhesion molecules (CAMS) participate intimately in atherosclerotic 
plaque formation. We hypothesized that serum levels of CAMS are directly related to ath- 
erosclerotic plaque burden and change in conjunction with a reduction in aortic plaque 
induced by statin therapy. 
Methods: Baseline and 6 month atherosclerotic plaque volume in the thoracic aorta was 
measured by combined transesophageal and surface MRI (TEMRI) in 24 patients treated 
with simvastatin 20-60 mg daily. Lipid levels, serum inflammatory markers [C- reactive 
protein (CRP), Interleukln-6 (IL-6) and Monocyte Chemoattractant Protein-i (MCP-I)] 
and CAMS [E-se&tin and P-selectin] were measured at baseline and 6 months. Gener- 
alized estimating equation modelling was used to investigate the association between 
CAMS and aortic plaque burden in 11 patients at 6 months. 
Results: Baseline TEMRI plaque volume correlated with E-se&tin (r=0.49, p< 0.02) and 
P-selectin (r=0.52, p=O.Ol). There was no correlation between baseline cholesterol val- 
ues or serum inflammatow markers and aortic olaaue volume. At 6 months. plaoue vol- 
ume was reduced by 13% from 3.5 f 0.3 cm3 at baseline to 3.0 * 0.3 cm3 (p c 0.02). 
Total cholesterol and LDL values decreased at 6 months (total cholesterol 210.6 * 10.2 
to 174.1 * 7.2 mg/dl and LDL 131.7 * 9.4 to 96.0 f 6.1 ‘mg/dl, ~~0.05 for both). At 6 
months the changes in E-selectm and P-selectin were strongly correlated with the 
decrease in aortic plaque volume (p=O.Ol). 
Conclusions: Baseline aortic atherosclerottc plaque burden by TEMRI correlated better 
with serum levels of E-selectin and P-selectin than with serum inflammatory markers or 
cholesterol values. After 6 months of statin therapy, changes in P-selectin and E-selechn 
were strongly correlated with the reduction in aortic plaque volume as measured by 
TEMRI. 
11:30 a.m. 
812-3 Beneficial Effects of Statin Therapy in the 
Atherosclerotic Human Aorta Are Related to Plaque 
Location 
Jolanda J. Went& Roberto Corti, Zahl A. Fayad, William F. Chaplin. Valentin Fuster. 
Juan J. Badimon, Mount Sinai School of Medicine, New York, NY 
Background: Atherosclerotic lesions preferentially develop at low shear stress areas an 
the arterial system, going in parallel with areas of endothelial dysfunction. Statin therapy 
is known to induce clinical benefits and even plaque regression, not only attributable to 
its hypolipidemic effects but also to the non-hypolipidemic (pleiotropic) effects, including 
endothelial Improvement. Because of the predilection sites of plaques and the observed 
anti-atherogenic effects of statins, the aim of this study was to investigate the potential of 
statins to operate at specific locations. 
Methods and Results MR images of the thoracic descending aorta of 9 asymptomatic 
hypercholesteremic patients (15 lesions) were acquired at baseline and 24 months after 
Itpid-lowering therapy by simvastatm. Contours of cross-sectional images were manually 
traced at the inner and outer vessel wall. At each cross section local wall thicknesses 
(LWT) were derived; the average wall thickness of each quadrant was calculated and the 
circumferential location and axial location as measured as distance from the arch (DA) 
were documented. Cross SectIons were divided into 4 groups based on the circumferen- 
tial (left or right side of the aorta) and axial location (DA> 6 cm or DA< 6cm). 114 cross 
sections were analyzed. At baseline, plaques were unevenly distributed among the four 
groups: 48% of the plaques LWT>Smm were located at the proximal, left side of the 
aorta, 28% at the proximal right side, while the other 24% of the plaques were distally 
located. Statin treatment resulted for lesions with LWT> 3mm, in an average plaque 
regression of 0.37 mm (IO%, pdO.05). Overall, plaque regression was directly related to 
the baseline wall thickness (LWTregresslon=0.50’L~~~~~,,“~-1.33 [mm], ~~0.05) and 
multwariate analysis showed plaque location as an independent predlctor. 
Conclusion Stalin therapy Induces regression of the atherosclerotic lesions in the 
descending thoracic aorta and this effect is dependent on pre-existing plaque size and 
location. Since flow patterns distal of the aortic arch are very characteristic and localized, 
these data might indicate the therapeutic effect of statins are modulated by local hemo- 
dynamics. 
11:45 a.m. 
812-4 Novel Photopoint Photodynamic Therapyjor the 
Treatment of Atherosclerotic Plaques 
Ron Waksman, Laurent Leborgne, Rufus Seabron, David Hellinga. Robert Scott, Travis 
Moore, John France, Steven Rychnovsky, Pauline McEwan, Washington Hospital 
Center, Washington DC, Mirvant Corporation, Santa Barbara, CA 
Background In humans, rupture of vulnerable plaques is one of the leading causes of 
cardiovascular-related mortality. The current therapies for atherosclerosis focus on cho- 
lesterol lowering and reducing inflammation without affecting the proliferative cell types 
that cause plaque progression. intravascular Photopoint Photodynamic Therapy (PDT) is 
a combination therapy that utilizes a photo activated drug and a light-emitting catheter to 
eliminate undesirable cell populations. The aim of the present study is to assess the effi- 
cacy of Photopoint as a therapy for the elimination of atherosclerotic plaque cell popula- 
tions with a view to inducing plaque stablizationlregression. 
Methods: New Zealand White rabbits (n=l6) were fed a 1% cholesterol diet followed by 
bilateral iliac balloon endothelial denudation. At 5wk post-denudation, rabbits received 
photosensitizer MV0611 (3mg/kg I.V.) followed by lkght delivery using a Mwavant cathe- 
ter-based diode laser (15J/cm2) at 4, 8 and 24 hrs post-injection. Control animals 
received either drug or light alone. Rabbits were sacrificed at 7d post-treatment and iliac 
arteries harvested for histopathology and immunohlstochemistry. 
Results: Maximum elimination of plaque cell nuclei was achieved at 6 and 24 hours drug 
incubation (78 f 6%, 96i4%; pcO.001). Nuclear depletion was consistent throughout 
entire 2cm lengths of plaque. PDT induced complete elimination of macrophage ‘foam’ 
cells and other inflammatory cells with a corresponding reduction in ‘foam’ cell neutral 
lipid. At 7days post PDT, expression of P53 correlated with cell loss. There was no evi- 
dence of Inflammation, necrosis or thrombosis post Photopoint treatment. 
Conclusions: Photopoint PDT may prove to be an effective therapy for the treatment of 
vulnerable plaque. An important component of this treatment may be the removal of mac- 
rophages by apoptotic mechanisms. Studies to investigate the chronic effects of PDT are 
ongoing. 
Noon 
812-5 Motexafin Gadolinium Decreases Vascular Inflammation 
in a Rabbit Model of Atherosclerosis in the Presence of 
Ascorbate 
YI-Pina Sun, Annette Byrne. Quan Zheng, Darren Magda. Richard Miller, Krishnankutty 
Sudhir. Pharmacyclics, Inc., Sunnyvale, CA 
Background: An Increase in vascular macrophage (Mac) burden in atherosclerosis 
(ATH) is a characteristic of vulnerable plaque. Motexafin gadolinium (MGd) is an 
expanded porphyrin that localizes in plaque and generates reactive oxygen species 
@OS) in the presence of reducing metabolites like ascorbate (Ax). Methods and 
Results: To study the synergic effects of MGd and Asc on ATH, 42 rabbits were fed a 
2% chol diet for 6 weeks (2 wks before and 4 wks after ~lrac balloon denudation), and 
then randomized to 6 groups: (1) Controls; (2) MGd (lOmg/kg i.v.); (3) Ax (0.5g/kg I.v.); 
(4) Asc 4h prior to MGd; (5) MGd + ASC simultaneously; (6) Asc 4h after MGd. After 4 
more wks on a normal diet, rabbits were sacrificed and aortic surface plaque (Sudan IV 
